MAIA Biotechnology Reports >2-Year Survival in Phase 2 NSCLC Trial

What Happened

• MAIA Biotechnology, Inc. filed a Current Report on Form 8-K on March 31, 2026, to issue a press release titled “MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non‑Small Cell Lung Cancer.”
• The company reported that eight patients in its ongoing Phase 2 NSCLC (non‑small cell lung cancer) trial have overall survival (OS) exceeding two years. The press release is attached as Exhibit 99.1 to the 8‑K.

Key Details

• Date filed: March 31, 2026 (Form 8‑K Item 8.01).
• Number of patients reported with OS > 2 years: 8.
• Trial stage and indication: Ongoing Phase 2 clinical trial in non‑small cell lung cancer.
• The filing includes the company’s standard forward‑looking statements cautioning that results are preliminary and subject to risks and uncertainties.

Why It Matters

• For investors, the report highlights promising clinical outcome data from MAIA’s Phase 2 program in NSCLC — durable overall survival in a subset of patients is a meaningful early clinical signal.
• This 8‑K conveys clinical progress but does not provide detailed efficacy or safety data, regulatory filings, or financial results. The company’s forward‑looking statement disclaimer underscores that these observations are preliminary and not guarantees of future outcomes.